Start-Up Veteran Joins Atlanta Catheter Therapies as CEO
Atlanta Catheter Therapies is an early stage research and development medical device company with an innovative and targeted portfolio of catheter technologies for the treatment of vascular disease and restenosis. ACT has developed a revolutionary drug delivery device for the treatment of restenosis (re-blockage of blood vessels) and is developing devices for endovascular debulking (clearing of blocked blood vessels).
"Our focus at ACT is on substantially improving patient care and lowering healthcare costs related to the treatment of vascular disease and restenosis," said Fitzpatrick. "Our role in product development includes design, IP patent filing, engineering, working prototyping, bench testing, animal testing, and regulatory approvals.
"Once the device is ready for human trials, manufacturing, sales and distribution, ACT will out-license or sell each device technology to a strategic partner," he added.
With 24 years of diverse, entrepreneurial business and healthcare experience, Fitzpatrick has a proven track record of delivering results, including running PJ Fitzpatrick Executive Advisory Group, which provides interim and fractional C-level and board engagements to early stage and small companies.
Fitzpatrick has completed over 20 merger and acquisition transactions with a combined value in excess of $100 million, and has been involved with numerous start-ups, turnarounds, roll-ups and integration of acquired companies with a range of public, private and venture-backed financing. With an in-depth knowledge of medical devices, clinical and patient care services, developing strategic alliances, multi-site and multi-state state operations, education and international recruiting and staffing, Fitzpatrick brings a rich skill set and knowledge base to his role with ACT.
Learn more at www.atlcath.com.
Media Contact: Lynn Hood Email Contact 678-427-5040 Company Contact: Paul Fitzpatrick Email Contact 770-321-8439